Gossamer Bio’s Post

The Patient Organisations Committee (POC) of International League of Dermatological Societies ( ILDS) encourages patients' voice and builds global alliances on building more support to our patients community.Patients are at the top of our priority as Dermatologists',and we hope to build stronger and more sustainable networks with support of our member organisations#ildsderm#patientorganisationcommitteeilds#iadvl#pigmentarydisorderssociety#womensdermatologicsociety

The Patient Organisations Committee (POC) of International League of Dermatological Societies ( ILDS )encourages patients' voice and builds global alliances on building more support to our patients community.Patients are at the top of our priority as Dermatologists',and we hope to build stronger and more sustainable networks with support of our member organisations#ildsderm#patientorganisationcommitteeilds#iadvl#pigmentarydisorderssociety#womensdermatologicsociety

Hear what Eric Hughes, Teva’s Executive Vice President, Global R&D and Chief Medical Officer, about the future of care for Tardive Dyskinesia (TD), a debilitating disorder characterized by involuntary repetitive body movements. Discover the significance of collaboration, prioritizing treatment innovation, education, and support for the TD community. Read more from him: https://lnkd.in/gqgCi8td #TDAwarenessWeek #TardiveDyskinesia #Tevapharm

🙌🏼 Tokenism in clinical trials for rare disease patients refers to the superficial inclusion of these individuals without genuinely considering their unique needs or adequately representing their conditions in the research. This practice can undermine the development of effective treatments for rare diseases, as it fails to capture the full spectrum of patient experiences and the specific challenges they face. 🔹 Tokenism may result from a lack of understanding, limited patient populations, or the drive to meet diversity quotas rather than a sincere effort to integrate meaningful patient involvement. 👨🏽⚕️ Addressing tokenism requires a more thoughtful and committed approach to patient recruitment and engagement, ensuring that clinical trials for rare diseases are designed with the genuine intention of understanding and addressing the specificities of these conditions, thereby leading to more relevant and impactful medical advancements. #skycrng #clinicalnursingleadership #hospitalcare #nurseleadership #patientoutcomes #healthcareleadership

Connecting with the right respondents is one of the first steps to a successful research study. Rare Patient Voice can help! With 145,000+ patients and family caregivers across 1,500+ rare and non-rare diseases in nine countries, all signed up with RPV and eager to take part, we will make recruitment fast and easy for your team. In fact, we've been called the "gold standard" in patient recruitment! Check out what some of our valued clients have had to say. #PatientRecruitment #research #GoldStandard

Is your organization passionate about addressing rare disease disparities and inspiring the next generation of medical professionals? The Call for Host-Site applications for the RDDC Fellowship is now open until March 15, 2024, at 11:59 pm EST! This program aims to empower fellows to tackle rare disease challenges, with emphasis on achieving greater equity for all. By collaborating with rare disease organizations, host sites provide invaluable experiences for fellows to make a difference. If your organization is interested in becoming a host site, apply here: https://lnkd.in/ei56vbjr Benefits of Hosting an RDDC Fellow: - Address unmet community needs - Infuse additional capacity and expertise - Cost-effective collaboration - Expand your network of rare disease partners - Inspire the next generation of healthcare professionals Help us spread the word by sharing this opportunity with other organizations who might be a great fit! Together, let's make a difference in rare disease advocacy and healthcare. #RareDisease #RDDC

At SMS Clinical Research, we're dedicated to advancing understanding and treatment for all those affected by this complex condition. Let's join hands to make a difference! 💙 #Schizophrenia #RSV #PinkEye #FindACure #HealthcareInnovation #BeAPartOfTheSolution #Mesquite #SMSClinicalResearch #HealthyLiving #ClinicalTrial #PatientCare #MedicalResearch #ClinicalTrials #Covid19 #HealthScience #ClinicalStudy #ResearchTrial

Over 700,000 people worldwide are living with Myasthenia Gravis (MG), a rare neuromuscular disease. In time for #MGAwarenessMonth, Huma is proud to introduce HumaMG, an innovative digital care platform designed specifically to help patients and their care teams monitor and manage the effects of MG. HumaMG makes it easy for patients to track their symptoms, receive timely reminders for their medication, and access educational resources tailored to their condition. Care teams can remotely monitor patient progress, identify potential issues early, and adjust treatments accordingly. We’re proud to be working with people living with MG, patient advocacy groups, and key opinion leaders in the MG space to continually enhance HumaMG, making it even more suited to the unique needs of MG patients and care teams. Together, we can make a meaningful difference in the lives of patients and their families. Myasthenia Gravis Foundation of America, Inc. #MGawareness #MyastheniaGravis #HumaMG #HealthTech

What are the latest developments in burn wound care? Join the discussion in South Africa at the Burns & Scientific Symposium in Cape Town, where experts will address the crucial issues facing clinicians today. Don't miss a chance to get expert tips and guidance on effective technologies, practical clinical pathways and patient case studies. Register here: https://bit.ly/3JUHIg9 Learn how we're shaping what's possible in wound care. #woundcare #burns

Ken's Medical Odyssey: A Journey Through Complex Diagnosis 🔍 Ken has had an intricate health journey. His path to understanding his condition was filled with extensive tests and treatments, navigating the complexities of medical diagnostics. After encountering numerous misdiagnoses, his persistence led to the discovery of hypermobile Ehlers-Danlos syndrome (hEDS), mast cell activation syndrome (MCAS), and dysautonomia. 🧪 Ken underwent a myriad of tests and trials to rule out other conditions, showcasing the often challenging road to a correct diagnosis. ⚕️From multiple ENTs and PCPs, to pain doctors and neurosurgeons, Ken saw multiple health professionals, many of whom ruled out his symptoms as anxiety or "common migraines." 📖 Read Ken's story and medical experiences here, and his hope to build a center dedicated to research, education, and patient advocacy: https://lnkd.in/emztmuBu Have you or someone you know faced similar challenges in getting a diagnosis? What was the point that changed everything for you? #MedicalJourney #EhlersDanlosSyndrome #HealthAwareness